BusinessSeeThruEquity Initiates Coverage on AXIM® Biotech (OTC: AXIM) With a Target Price of $17.0By Nasdaq OMXMay 16, 2017, 1:04 PM UTC
BusinessDrugDev and Informa Partner to Transform Site Selection for Global Clinical Trials by Integrating Citeline Investigator Data with DrugDev Spark™By Nasdaq OMXMay 10, 2017, 9:22 AM UTC
BusinessCureGrail Launches Collaborative, System-Level Platform to Accelerate Drug Development & Cure DiscoveryBy Nasdaq OMXFeb 21, 2017, 5:46 PM UTC
BusinessPurdue-affiliated pharmaceutical company launches product to produce rare disease-fighting compoundsBy Nasdaq OMXFeb 15, 2017, 1:15 PM UTC
BusinessNeothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous FatBy Nasdaq OMXDec 23, 2016, 1:00 PM UTC
BusinessNeothetics Announces Leadership Change and Preliminary Update on LIPO-202By Nasdaq OMXFeb 18, 2016, 9:00 PM UTC
